While upregulation of CEACAM5 and CXCL17 seems to have a biological explanation, the underlying mechanism of the lower systemic levels of both important cancer related receptor tyrosine kinases, VEGFR2 and ERBB3, in lung cancer patients, remains elusive. This evidence concerns the gene CXCL17 and lung carcinoma.